Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications - Neurodegenerative -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (338)	3/18/2010 3:55:09 AM
From: idos	Respond to of 448

Interesting and may in fact make sense biologically - the body is trying its best but sometimes fails, and while overdoing it, creates another problem. Their data showing greater potency for Aß42 also makes sense as the Alzheimer's Disease Neuroimaging Initiative (ADNI) latest data showed correlation between CSF Aß42 levels and cognitive decline in AD. neurology.org Even if this is just another theory, at least a new drug candidate for Candida might be developed :-)